Maternal Insulin-like Growth Factor-II Promotes Placental Functional Development Via the Type 2 IGF Receptor in the Guinea Pig
Introduction
Fetal growth is dependent on the placental supply of nutrients. This is determined by the mother's ability to acquire nutrients and the capacity of the placenta to transfer these to the fetus. Impaired placental development leads to failure of the materno-placental supply and results in intrauterine growth restriction (IUGR) [1] and other major pregnancy complications, such as miscarriage [2], preeclampsia [1] and preterm birth [3] which are significant causes of maternal and fetal mortality and morbidity. In addition, IUGR is associated with cardiovascular disease, obesity and diabetes in adult offspring [4]. Understanding the molecular regulation of placental development may identify potential causes of, and possible therapeutic targets for, impaired placentation and these adverse consequences.
The insulin-like growth factors (IGFs) are anabolic polypeptides which appear to have a major role in placentation. Both IGF-I and IGF-II are major determinants of fetal growth [5], [6], [7] and are highly expressed by the mother and fetus in most species [8]. IGF-II is also abundantly produced by the placenta [9]. Maternal plasma IGF-I and IGF-II concentrations increase during early pregnancy in several species (as reviewed by ref. [10]) including humans [11]. These may play an endocrine role in placentation as both reduced plasma IGF-I [12] and increased circulating concentrations of inactive pro-IGF-II peptide [13] are associated with placental dysfunction and fetal growth restriction in women. Furthermore, reductions in maternal plasma IGFs in guinea pigs exposed to food restriction correlate with markers of delayed structural and functional maturation of the placenta and reduced fetal growth [14], [15], [16].
Furthermore, we have also shown that increasing maternal systemic concentrations of IGF in the guinea pig, by infusing IGF-I or IGF-II during early to mid pregnancy, enhances fetal growth and survival near term [17]. Early pregnancy infusion of either IGF also increased placental glucose transport and the concentration of fetal circulating amino acids [17], [18]. Despite similar outcomes for fetal growth and survival and placental function, each IGF exerted distinct effects on placental growth and maternal body composition, suggesting that maternal IGFs may play complementary roles in placentation and pregnancy to ensure fetal growth and survival.
In the guinea pig, maternal IGF-I treatment in early to mid pregnancy did not alter placental development but maternal adipose stores were reduced in late pregnancy, which may reflect increased diversion of substrates to the conceptus [17]. In contrast, maternal IGF-II treatment did not affect maternal body composition but enhanced development of the placental exchange region (labyrinth) into late gestation [17]. This altered placental development correlated with improved placental transport capacity [18] and suggests that IGF-II effects on fetal growth were likely to be mediated via an impact on placental development.
IGF-II can alter trophoblast phenotype and function in vitro and such actions may underlie these reported consequences of exogenous IGF-II administration in the pregnant guinea pig. IGF-II promotes murine trophoblast differentiation by transforming ectoplacental cone cells (trophoblast stem cells) into trophoblast giant cells in vitro [19]. IGF-II also stimulates human placental trophoblast proliferation [20], migration [21], invasion [22], matrix metalloproteinase synthesis and activity [20] and nutrient uptake [23] in vitro.
The distinct effects of exogenous IGF-I and IGF-II during pregnancy in the guinea pig may arise from different interactions of the IGFs with various receptors. All three receptors, insulin receptor (InsR) [24] and the type 1 and 2 IGF receptors (IGF1R and IGF2R, respectively) [17], are expressed by the guinea pig placenta and are ubiquitously expressed by maternal tissues. IGF-I has negligible affinity for IGF2R and InsR [25], [26], thus its actions are likely to be mediated by the IGF1R. IGF-II, on the other hand, can bind all three receptors, making it difficult to decipher which one is responsible for mediating the effects of exogenous maternal IGF-II. It is possible that IGF-II actions on the placenta may be mediated by the InsR which has been implicated in mediating IGF-II actions on fetal growth in mice [27] or by the IGF2R, which it binds with much greater affinity than the IGF1R [25]. Although, IGF2R initially appeared to function only as a clearance receptor for IGF-II, as Igf2r gene ablation in mice leads to increased serum and tissue levels of IGF-II [28], more recent lines of evidence suggest that IGF-II can signal via this receptor and affect a range of cellular functions such as differentiation, migration and apoptosis in a variety of cell types [29], [30], [31], [32], [33], [34], [35], [36]. Furthermore, IGF-II acting via IGF2R promotes human placental trophoblast migration in vitro [21].
This investigation aimed to determine if the IGF2R mediates the actions of exogenous IGF-II in the mother by comparing the impact of IGF-II with that of an IGF-II analogue, Leu27-IGF-II, which only binds the IGF2R. Leu27-IGF-II has a significantly reduced binding capacity for the IGF1R and InsR compared to IGF-II (80 and 220-fold lower affinity, respectively), while its affinity for IGF2R is unaltered [37] with only slightly reduced affinity for IGF binding proteins [38].
Section snippets
Animals
This study was approved by the University of Adelaide Animal Ethics Committee. Pregnant female guinea pigs (IMVS coloured strain, ∼500 g, 3–4 months old) were housed individually in the University of Adelaide Medical School Animal House (12 h light: 12 h dark cycle) and provided with food and water ad libitum. Females were assigned to form three groups of similar mean weight at mating. On day 20 of pregnancy (day 1 = day a copulatory plug was observed or the day after females were paired with a
Maternal body composition
Neither maternal IGF-II (n = 5) nor Leu27-IGF-II (n = 4) treatment affected maternal weight gain during pregnancy compared with vehicle (n = 6) (data not shown). IGF-II did not affect any tissue or organ weight in absolute or relative to body weight terms. Leu27-IGF-II reduced the absolute weights of the maternal retroperitoneal and interscapular fat depots compared to vehicle (−31%, P = 0.043 and −10%, P = 0.049, respectively) and the fractional weight of the former, compared to vehicle and IGF-II (both
Discussion
We have previously shown that treatment of the pregnant guinea pig with IGFs from early to mid gestation enhances placental transport and growth of the fetus near term, with distinct effects of IGF-I and IGF-II on placental structure and maternal body composition. To determine if the IGF2R mediates the actions of exogenous IGF-II in the mother, the impact of IGF-II was compared to that of an IGF-II analogue, Leu27-IGF-II, which only binds the IGF2R. The present study demonstrates for the first
Acknowledgements
We would like to thank GroPep Pty. Ltd. for supplying recombinant IGF-II and Leu27-IGF-II analogue. We would also like to thank Kirsty Pringle for her assistance in the guinea pig post-mortems. This work was supported by a NH&MRC project grant to CTR.
References (46)
- et al.
Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes
Am J Obstet Gynecol
(2003) - et al.
Role of insulin-like growth factors in embryonic and postnatal growth
Cell
(1993) - et al.
Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r)
Cell
(1993) The insulin-like growth factors and feto-placental growth
Placenta
(2003)- et al.
Spatial and temporal patterns of expression of messenger RNA for insulin-like growth factors and their binding proteins in the placenta of man and laboratory animals
Placenta
(2000) - et al.
Maternal nutrition affects the ability of treatment with IGF-I and IGF-II to increase growth of the placenta and fetus, in guinea pigs
Growth Horm IGF Res
(2001) - et al.
Circulating levels of insulin-like growth factors increase and molecular forms of their serum binding proteins change with human pregnancy
Biochem Biophys Res Commun
(1990) - et al.
Circulating insulin-like growth factor (IGF)-I and IGF binding proteins-1 and -3 and placental development in the guinea-pig
Placenta
(2002) - et al.
Maternal food restriction reduces the exchange surface area and increases the barrier thickness of the placenta in the guinea-pig
Placenta
(2001) - et al.
Altered placental structure induced by maternal food restriction in guinea pigs: a role for circulating IGF-II and IGFBP-2 in the mother?
Placenta
(2001)
Autocrine-paracrine regulation of human trophoblast invasiveness by insulin-like growth factor (IGF)-II and IGF-binding protein (IGFBP)-1
Exp Cell Res
Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development
Dev Biol
Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds
Dev Biol
The insulin-like growth factor II (IGF-II)/mannose 6-phosphate receptor mediates IGF-II-induced motility in human rhabdomyosarcoma cells
J Biol Chem
The design, expression, and characterization of human insulin-like growth factor II (IGF-II) mutants specific for either the IGF-II/cation-independent mannose 6-phosphate receptor or IGF-I receptor
J Biol Chem
Binding of mutants of human insulin-like growth factor II to insulin-like growth factor binding proteins 1-6
J Biol Chem
Immunohistochemical identification of epithelial and mesenchymal cell types in the chorioallantoic and yolk sac placentae of the guinea-pig
Placenta
The guinea pig placenta: model of placental growth dynamics
Placenta
Placental anionic and cationic amino acid transporter expression in growth hormone overexpressing and null IGF-II or null IGF-I receptor mice
Placenta
Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants
Br J Obstet Gynaecol
Defective haemochorial placentation as a cause of miscarriage: a preliminary study
Br J Obstet Gynaecol
In utero programming of chronic disease
Clin Sci (Lond)
A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting
Nature
Cited by (23)
Targeting the Dysfunctional Placenta to Improve Pregnancy Outcomes Based on Lessons Learned in Cancer
2021, Clinical TherapeuticsCitation Excerpt :In terms of pregnancy, a number of animal studies49,50 have been performed using the adenoviral VEGFA165 vector in models of FGR to increase the expression of VEGF in placental and uterine tissue. In these studies, outcomes for fetal growth were positive with treatment enhancing placenta function over placenta growth (Table I).49–67 As with VEGF, numerous studies have targeted the IGF1/IGF2 signaling pathway in the development of cancer therapeutics (Table I).
Maternal insulin-like growth factor 1 and 2 differentially affect the renin-angiotensin system during pregnancy in the guinea pig
2015, Growth Hormone and IGF ResearchCitation Excerpt :Whether the exogenous administration of IGF2 in guinea pigs in early pregnancy improves placental structural differentiation in the short term (mid pregnancy) has yet to be evaluated. Interestingly, treatment with Leu27IGF2, an analogue specific for the IGF2R, induces similar placental and fetal outcomes near term to IGF2 treatment [3] Furthermore, IGF2 signaling through IGF2R affects trophoblast survival in vitro [4], which indicates that the effects of IGF2 on placental development might be mediated through the IGF2R. Both IGFs and RAS regulate placental function and development and there is cross-talk between these two systems in other tissues [5–10]; therefore, it is likely that these two systems also interact to regulate placental development.
System A activity and vascular function in the placental-specific Igf2 knockout mouse
2011, PlacentaCitation Excerpt :In the mouse, IGF-II expression was found to be strongest in the decidua adjacent to maternal blood vessels [12], suggesting a role in angiogenesis, perhaps through induction of vascular endothelial growth factor. Other studies in guinea pig have demonstrated that IGF-II supplementation in early to mid-pregnancy results in an increase in the maternal blood spaces by 46%, postulated to arise from increased trophoblast proliferation and invasion of maternal vascular bed resulting in an enhanced blood flow to the placenta [13,14]. It is therefore possible that the lack of P0 Igf2 transcript in the placenta of P0 mice affects uteroplacental vascular function, contributing to the FGR observed in these animals.
Expression of the insulin-like growth factor system in skeletal muscle during embryonic and postnatal development in the first filial generation pigs from Erhualian and Yorkshire reciprocal crosses
2011, General and Comparative EndocrinologyCitation Excerpt :Additionally, IGF-II binds to IGF-IIR with reduced affinity and IGF-I binds to IGF-IIR with low affinity [10]. IGF-II during early gestation can act in part via IGF-IIR to persistently enhance placental functional development and promote fetal growth [48]. In this study, IGF-IR mRNA levels were significantly higher before birth compared with after birth, except for D120 in the ST muscle of EY pigs (Figs. 1c and 2c).
Milk - The promoter of chronic Western diseases
2009, Medical HypothesesDHA Supplementation during Pregnancy in Women with Obesity Normalizes IGF2R Levels in the Placenta of Male Newborns
2023, International Journal of Endocrinology